Quetiapine
- 1 lab in 1 country
- Funder: Novo Nordisk Fonden
- Humans1
- In silico1
Associations
1Major adverse cardiovascular events
downin humans1
1 study
Major adverse cardiovascular events
downin humans1
Quetiapine lowers the risk of major adverse cardiovascular events in humans (IRR 0.68, 95% CI 0.58 to 0.80).
“quetiapine (0.68, 95% CI 0.58 to 0.80)”
Humanscompared with risperidone, first 30 days of treatment30 days
Journal of the American Heart Association1 Sep 2015
Latest
2 in 12 monthsFigshare
GHS-CVRAI: A Receptor-Resolved Cardiovascular Risk Amplification Index for Antipsychotic Prescribing Across Psychiatric Disorders
Preprint: computational studyBiomarkers
Journal of the American Heart Association
Association of Selected Antipsychotic Agents With Major Adverse Cardiovascular Events and Noncardiovascular Mortality in Elderly Persons
Cohort study of 91,774 peoplePopulations